APATONE®:

Apatone ® is a clinical phase investigational new drug based on the Norton-Simon hypothesis. This view suggests that tumors given less time to re-grow between chemotherapy treatments are more likely to be destroyed. Apatone enhances efficacy by selectively lowering reduced glutathione and pyridine nucleotides. The drug has successfully completed phase I/IIa clinical study for safety and as an oral monotherapy for late-stage prostate cancer. In a report to the FDA, investigators Dr. A. Diokno, Chief Medical Officer for William Beaumont Hospital (Michigan) and Dr. J. Summers, Director for Urologic research at Summa Hospital (Ohio), reported: "There is evidence of therapeutic benefit based on PSA kinetics. The more advanced the disease, the more pronounced the effect seemed to be. Additional studies appear warranted for the use of Apatone as a co-adjuvant, or for salvage chemotherapy in the treatment of late stage prostate cancer." Apatone is currently under consideration for clinical study with chemotherapy in chemorefractory patients with no clinical options that are known to prolong life. Potential applications include augmentation of chemotherapy to allow lower, less toxic doses of common chemotherapeutic agents such as gemcitabine, doxorubicin, 5FU, cyclophosphamide and others.

Cell treated with Apatone® Apatone® is a combination of menadione sodium bi-sulfate(Figure A) and Asorbic Acid (Figure B).

Cell Death Movie

To make an online donation to the Appatone Development Project please click here Please specify your that your donation to goes to the Apatone Development Project by entering number: 53293 in the Established Fund Name Your donation of any amount is greatly appreciated!